ストックスクリーナーアプリを入手
675.19
0.45%
3.04
アフターアワーズ：
672.60
-2.59
-0.38%
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law - marketscreener.com
Lobbying Update: $630,000 of REGENERON PHARMACEUTICALS INC lobbying was just disclosed - Quiver Quantitative
REGN Maintained by Guggenheim -- Price Target Raised to $1000 - GuruFocus
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - PR Newswire
Regeneron stock holds its ground as sales and earnings stay strong - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals Limited and Regeneron Pharmaceuticals, Inc. Enter into Strategic Collaboration to Jointly Develop and Commercialize Next-Generation Radiopharmaceutical Therapies and Advance Multiple Novel Oncology Programs - marketscreener.com
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - lincolnjournal.com
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff - GlobeNewswire
Albany's construction sector signals growth from Regeneron's $2B expansion to rising contractor billings - MarketScale
Regeneron stock holds after 2025 revenue and earnings growth - Ad-hoc-news.de
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
Regeneron Pharmaceuticals (REGN) Jefferies Global Healthcare Conference Summary - Quartr
Regeneron stock trades steady as Eylea and Dupixent growth support earnings - ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – REGN - mykxlg.com
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 - marketscreener.com
Regeneron stock trades near recent highs as Dupixent growth and pipeline updates support valuation - ad-hoc-news.de
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Regeneron (REGN) Stock Looks Discounted As It Holds A 24% Gain - simplywall.st
REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In? - Yahoo Finance
REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. - PR Newswire
Regeneron stock trades steady as Eylea and Dupixent revenue support earnings trajectory - ad-hoc-news.de
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
Regeneron Investor Sues Over Cancer Drug Trial Miss, Stock Drops - Bloomberg Law News
Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Business Wire
Price-Driven Insight from (REGN) for Rule-Based Strategy - Stock Traders Daily
Regeneron Pharmaceuticals (Ondo Tokenized) price today, REGNON to USD live price, marketcap and chart - CoinDesk
Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap? - simplywall.st
Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu - GuruFocus
Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma - Stocktwits
Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Regeneron stock holds firm as the focus shifts to the pipeline - Ad-hoc-news.de
Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron’s (REGN) Investment Narrative? - simplywall.st
Own Regeneron For Biotech Growth? Incyte Is Making Its Case. - Trefis
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2 - Yahoo Finance
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $730 - Moomoo
Cantor Fitzgerald reiterates Overweight on Regeneron stock - Investing.com
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $856 - Moomoo
Regeneron Pharmaceuticals (REGN): Investor Outlook On Its 23.77% Potential Upside - DirectorsTalk Interviews
Regeneron Cites Medtronic Ruling In Amgen Bundling Case - Law360
REGN Maintained by Piper Sandler -- Price Target Lowered to $854 - GuruFocus
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $854 - Moomoo
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855 - Moomoo
REGN Maintained by Morgan Stanley -- Price Target Lowered to $73 - GuruFocus
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Narrows Amgen Challenges in Case Over Eylea Biosimilar - Bloomberg Law News
Is Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut? - Insider Monkey
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Cuts Target Price to $730 - Moomoo
A Quick Look at Today's Ratings for Regeneron Pharmaceuticals(REGN.US), With a Forecast Between $696 to $769 - Moomoo
Regeneron Pharmaceuticals balances growth prospects as a major biotech player. The company continues - ad-hoc-news.de
Morgan Stanley Adjusts Price Target Regeneron Pharmaceuticals to $730 From $788, Maintains Equalweight Rating - Moomoo
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims - Law360
Regeneron and Telix Announce Strategic Radiopharma Collaboration - Regeneron
Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron director Arthur Ryan sells $130,030 in stock By Investing.com - Investing.com South Africa
3.37%
0.48%
大文字化:
|
ボリューム (24 時間):